Nuvation Bio Inc (NYSE:NUVB) shares traded 20.38% higher at $1.16 on Wall Street last session.
In accordance with the data, 6 analysts cover Nuvation Bio Inc (NYSE:NUVB). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $1.80, we find $4.75. Given the previous closing price of $0.96, this indicates a potential upside of 394.79 percent. NUVB stock price is now -14.24% away from the 50-day moving average and -32.22% away from the 200-day moving average. The market capitalization of the company currently stands at $255.13M.
It has been rated a hold by 2 analysts and a buy by 4. Brokers who have rated the stock have averaged $4.08 as their price target over the next twelve months.
With the price target reduced from $5 to $2, Jefferies Downgraded its rating from Buy to Hold for Nuvation Bio Inc (NYSE: NUVB).
In other news, NODELMAN OLEG, Director bought 53,000 shares of the company’s stock on Feb 21. The stock was bought for $72,138 at an average price of $1.36. Upon completion of the transaction, the Director now directly owns 12,674,775 shares in the company, valued at $14.7 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 20, Director NODELMAN OLEG bought 117,100 shares of the business’s stock. A total of $159,490 was incurred on buying the stock at an average price of $1.36. This leaves the insider owning 12,621,775 shares of the company worth $14.64 million. A total of 37.31% of the company’s stock is owned by insiders.
Nuvation Bio Inc (NYSE: NUVB) opened at $0.9900 on Wednesday. During the past 12 months, Nuvation Bio Inc has had a low of $0.95 and a high of $2.55. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 47.51, and a quick ratio of 47.51. The fifty day moving average price for NUVB is $1.3527 and a two-hundred day moving average price translates $1.7113 for the stock.
The latest earnings results from Nuvation Bio Inc (NYSE: NUVB) was released for Jun, 2023.
Nuvation Bio Inc(NUVB) Company Profile
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
